Cingulate Inc., a pharmaceutical company, has announced a Special Meeting of Stockholders to be held virtually on August 23, 2024. The meeting will address two key proposals: the Issuance Proposal and the Adjournment Proposal. The Issuance Proposal seeks stockholder approval to comply with Nasdaq Listing Rule 5635(d) for the issuance of shares underlying certain warrants issued pursuant to agreements with investors and H.C. Wainwright & Co., LLC. These warrants could potentially exceed 20% of the company's common stock outstanding prior to the issuance. The Adjournment Proposal, if necessary, will allow the meeting to be adjourned to solicit additional votes if there are insufficient votes for the Issuance Proposal. The record date for determining stockholders entitled to vote is set for June 28, 2024. The...Show More

Cingulate Inc., a pharmaceutical company, has announced a Special Meeting of Stockholders to be held virtually on August 23, 2024. The meeting will address two key proposals: the Issuance Proposal and the Adjournment Proposal. The Issuance Proposal seeks stockholder approval to comply with Nasdaq Listing Rule 5635(d) for the issuance of shares underlying certain warrants issued pursuant to agreements with investors and H.C. Wainwright & Co., LLC. These warrants could potentially exceed 20% of the company's common stock outstanding prior to the issuance. The Adjournment Proposal, if necessary, will allow the meeting to be adjourned to solicit additional votes if there are insufficient votes for the Issuance Proposal. The record date for determining stockholders entitled to vote is set for June 28, 2024. The company emphasizes the importance of stockholder votes, whether or not they plan to attend the virtual meeting. Cingulate Inc. has already completed a Private Placement, resulting in the issuance of new warrants, and now requires stockholder approval to issue the shares underlying these warrants. Failure to approve the Issuance Proposal could prevent the exercise of the warrants and impact the company's ability to raise approximately $3.9 million in gross proceeds, potentially affecting its operations.